Following positive results in human xenograft models which showed potentiation of cytotoxicity when anti-EGFR agents were administered with chemotherapy [66], several studies investigated monoclonal antibodies such as cetuximab and matuzumab and oral receptor tyrosine kinase inhibitors of EGFR like gefitinib and erlotinib in ovarian cancer [67,68,69]. Here, EGFR is linked to ovarian carcinoma.